Oral nanozyme-engineered probiotics for the treatment of ulcerative colitis

Zhao, Huan; Du, Yurong; Liu, Lei; Du, Yabing; Cui, Kang; Yu, Pu; Li, Li; Zhu, Yong‐Guan; Jiang, Wei; Li, Zhen; Tang, Hao; Ma, Wei

doi:10.1039/d2tb00300g

Cited by 20 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, we found that both postbiotics and probiotics administration protected against DSS-induced colitis, reflected by the decreased histology scores in Postbiotic and Probiotic groups compared with DSS group. However, neither the postbiotic nor probiotic application significantly affected weight loss, DAI, and colon length in mice with colitis, which were inconsistent with previous findings showing protective effects in these aspects [39][40][41] . The discrepant results between this and previous studies in the protective effect against DSS-induced colitis could be due to the different strains of postbiotics and probiotics used and different experimental design between studies.…”

Section: Discussioncontrasting

confidence: 96%

Stronger gut microbiome modulatory effects by postbiotics than probiotics in a mouse colitis model

Zhang

Feng

et al. 2022

npj Sci Food

View full text Add to dashboard Cite

Probiotics are increasingly used as adjunctive therapy to manage gastrointestinal diseases, such as ulcerative colitis. However, probiotic use has posed some safety concerns. Thus, postbiotics are proposed as alternatives to probiotics in clinical applications. However, no study has directly compared the clinical benefits of probiotics and postbiotics. This study compared the beneficial effect of postbiotics and probiotics derived from the strain, Bifidobacterium adolescentis B8598, in a dextran sulfate sodium (DSS)-induced experimental colitis mouse model. Four groups of mice (n = 7 per group) were included in this work: Control (received water plus saline), DSS (received DSS without postbiotic/probiotic), Postbiotic (received DSS plus postbiotic), and Probiotic (received DSS plus probiotic). Our results showed that intragastric administration of both probiotic and postbiotic ameliorated colitis, reflected by decreased histology scores in Postbiotic and Probiotic groups compared with DSS group (P < 0.05). The fecal microbiota alpha diversity was not significantly affected by DSS-, postbiotic, or probiotic treatment. However, the postbiotic treatment showed stronger effects on modulating the fecal microbiota beta diversity, composition, and metagenomic potential than the probiotic treatment. Overall, our findings suggested that probiotics and postbiotics had similar ability to improve disease phenotype but had distinct ability to regulate the gut microbiota and metabolic pathways in the context of ulcerative colitis. In view of the smaller safety concern of postbiotics compared with probiotics and its stronger modulatory effect on the host gut microbiota, we propose that postbiotics are to be considered for use as next-generation biotherapeutics in managing ulcerative colitis or even other diseases.

show abstract

Section: Discussioncontrasting

confidence: 96%

Stronger gut microbiome modulatory effects by postbiotics than probiotics in a mouse colitis model

Zhang

Feng

et al. 2022

npj Sci Food

View full text Add to dashboard Cite

show abstract

“…However, probiotics are easily caught or destroyed in advance, and only a few probiotics can reach the inflammatory bowel segment. Zhao et al used a Pt nanozyme-liposome coating to wrap a single probiotic, and the nanozyme coating effectively protected probiotics from strong digestive acids and enzymes. Oral administration of probiotics protected by a nanozyme coating can effectively treat ulcerative colitis in mice.…”

Section: Therapeutic Application Of Disease Microenvironment Remodeli...mentioning

confidence: 99%

“…The etiology and pathogenesis of infectious bowel disease (IBD) remain unclear and it is considered to be caused by the interaction of multiple factors, including environmental, genetic, infectious, and immune factors . A large number of studies have pointed out that nanozymes can be used to improve the inflammatory microenvironment in the intestinal tract and remove excess ROS to play a therapeutic role. ,,,, Zeng et al modified CeO 2 NPs with PEG, and the prepared PEG-CeO 2 NPs exerts a therapeutic effect on the mouse colitis model induced by sodium dextran sulfate (DSS). PEG-CeO 2 NPs can improve the inflammatory microenvironment by continuously scavenging ROS, down-regulating the levels of various proinflammatory cytokines, and inducing macrophage polarization and the Th1–Th17 reaction.…”

Section: Therapeutic Application Of Disease Microenvironment Remodeli...mentioning

confidence: 99%

Nanozyme-Based Remodeling of Disease Microenvironments for Disease Prevention and Treatment: A Review

Liu

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Nanomaterials that can mimic the activity of various enzymes have been studied extensively in the biomedical field in recent years. Nanozymes offer better stability and economic value in comparison to natural enzymes. Additionally, nanozymes have characteristics of nanomaterials, such as photothermal properties and designability, and therefore have considerable potential. The cellular microenvironment provides the basis for maintaining normal cell growth and function. Increasing evidence shows that imbalances in the homeostasis of the cellular microenvironment constitute a major factor in the development of many diseases. Nanozymes have received considerable attention in recent years as regulators of the cellular microenvironment. In this Review, research on the use of nanozymes to remodel the disease microenvironment is discussed. First, the definition, classification, and enzyme-like activities of nanozymes are introduced; several major disease microenvironments are summarized including tumor, inflammatory, and trauma microenvironments. The role of nanozymes in disease microenvironments and the main strategies for constructing intelligent and responsive nanozyme systems are discussed. The specific applications of nanozymes in remodeling the diseased microenvironment are highlighted. Finally, the therapeutic strategies of nanozymes to remodel the disease microenvironment are summarized and prospected. Nanozyme disease microenvironment remodeling is expected to become a major therapeutic strategy or an adjunct for the prevention and treatment of related diseases.

show abstract

“…They found that liposomes can protect the phages in the stomach and improve the activity of phages in the intestine. Zhao et al (2022) embedded Escherichia coli Nissle in liposome and found that damage to E. coli can be avoided by acids and enzymes in the GIT, and the colonization rate of E. coli Nissle was also improved, resulting in a better treatment of colonic inflammation and regulation of intestinal epithelial barrier homeostasis than the bare E. coli Nissle. Therefore, the use of liposomes to protect and deliver the probiotics and improve intestinal colonization function of probiotics to treat intestinal diseases has become a new trend.…”

Section: The Fate Of the Core Materials After Releasementioning

confidence: 99%

Specific surface modification of liposomes for gut targeting of food bioactive agents

Zhang

Pan

et al. 2023

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Liposomes have become a research hotspot in recent years as food delivery systems with attractive properties, including the bilayer structure assembled like the cell membrane, reducing the side‐effect and improving environmental stability of cargos, controlling release, extending duration of functional ingredients, and high biodegradable and biocompatible abilities in the body. However, the conventional liposomes lack stability during storage and are weak in targeted absorption in the gastrointestinal track. At present, surface modification has been approved to be an effective platform to shield these barricades and help liposomes deliver the agents safely and effectively to the ideal site. In this review, the gastrointestinal stability of conventional liposomes, cargo release models from liposomes, and the biological fate of the core materials after release were emphasized. Then, the strategies in both physical and chemical perspectives to improve the stability and utilization of liposomes in the gastrointestinal tract, and the emerging approaches for improving gut targeting by specifically modified liposomes and the intestinal receptors relative to liposomes/cargos absorption were highlighted. Last but not the least, the safety, challenges, and opportunities for the improvement of liposomal bioavailability were also discussed to inspire new applications of liposomes as oral carriers.

show abstract

Oral nanozyme-engineered probiotics for the treatment of ulcerative colitis

Abstract: Background: Probiotic-based therapy for ulcerative colitis (UC) is a novel and promising approach that has gained much popularity in recent years. However, probiotics may be easily captured and destroyed by...

Cited by 20 publications

References 42 publications

Stronger gut microbiome modulatory effects by postbiotics than probiotics in a mouse colitis model

Stronger gut microbiome modulatory effects by postbiotics than probiotics in a mouse colitis model

Nanozyme-Based Remodeling of Disease Microenvironments for Disease Prevention and Treatment: A Review

Specific surface modification of liposomes for gut targeting of food bioactive agents

Contact Info

Product

Resources

About